Deals channel feed – Endpoints News

Deals channel feed

M&A season starts early? CSL seals $11.7B acquisition of Vifor Pharma

4 years ago

As year-end deals start to sizzle, CSL moves a biotech buyout to the front burner with deal expected Tuesday — report

4 years ago

Eli Lilly's Van Naarden hands $380M cash to Flagship-backed upstart in major new oncology deal

4 years ago

Pfizer scoops up Arena and its S1P drug in $6.7B buyout — chasing Bristol Myers and capping a lengthy biotech turnaround

4 years ago

After investing in their Series B, Lilly bags a license for a batch of metabolic candidates

4 years ago

Billionaire BioNTech backers have been kicking the tires at Novartis' big generics arm — report

4 years ago

Viatris and Biocon mull pooling their biosimilars into a $10B standalone company — report

4 years ago

Biotech upstart gets $50M to test new virus-based therapies against solid tumors

4 years ago

'We're in': Roche and Genentech join forces on a multibillion-dollar discovery pact with a brash AI upstart

4 years ago

AstraZeneca grabs PhIII ATTR drug from Ionis — infusing $200M cash into struggling partner

4 years ago

Recordati acquires EUSA Pharma and its 4 rare disease drugs, but analysts question strategy behind the deal

4 years ago

The 2022 wave coming? Top analyst says Big Pharma will have more than $1T available to satisfy its growing appetite for biotech M&A

4 years ago

AstraZeneca nixes $8B Sobi buyout over fears a former drug would be sold to rivals — report

4 years ago

A Seattle biotech offloads lead eye drug in deal valued at $1B+ as it refocuses on emerging pipeline

4 years ago

Watch out, Roche: Novartis inks $1.5B deal to chase down prominent Parkinson’s target

4 years ago

GlaxoSmithKline, Oxford unveil new partnership pitting buzzy R&D advances against neurological disease

4 years ago

With only burns to show in gene therapy, Astellas inks deal with AAV specialist Dyno in push for a better capsid

4 years ago

Sanofi snaps up new vaccine candidate and devises mRNA game plan around it — but not for what you think

4 years ago

Looking past Big Pharma rivals, Blueprint buys a preclinical biotech for $250M+

4 years ago

Biotech billionaire Róbert Wessman engineers $450M deal for Alvogen subsidiaries

4 years ago

Merck's pause on an HIV program snowballs as a Gilead-partnered trial is shoved into limbo

4 years ago

Vaccibody gets a new name and loads up with nearly $1B in biobucks for new vaccine pact with Regeneron

4 years ago

GlaxoSmithKline places a risky bet on Arrowhead's RNA drug in the failure-strewn NASH field

4 years ago

Sanofi continues mRNA push in wake of Covid vaccine setback, partnering with China tech giant Baidu

4 years ago

First page Previous page 65 66 676869 70 71 Next page Last page